TNFRSF14
TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
Overview
Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signalling network. Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signalling between antigen presenting cells and lymphocytes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.92, animal model 0.27, genetic association 0.00, somatic mutation 0.95). IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
- 1 · What it is
TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.
- 2 · What goes wrong in cancer
Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signalling network.
- 3 · How drugs use it
No product in this corpus aims at TNFRSF14 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:11912 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92956 (protein name, function text, keywords and locations (REST API)); CIViC gene TNFRSF14 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000157873 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.68, skin cancer 0.51, lung cancer 0.52 (GraphQL API, CC0)); IntOGen TNFRSF14 (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signalling network. Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signalling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions. Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumour immune response. In the context of bacterial infection, acts as a signalling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines. Location: Cell membrane (UniProt). Locus 1p36.32 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)
- Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)
- Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TNFRSF14" OR ABSTRACT:"TNFRSF14" OR TITLE:"TNF receptor superfamily member 14" OR ABSTRACT:"TNF receptor superfamily member 14" OR TITLE:"Tumor necrosis factor receptor superfamily member 14" OR ABSTRACT:"Tumor necrosis factor receptor superfamily member 14" OR TITLE:"TR2" OR ABSTRACT:"TR2" OR TITLE:"LIGHTR" OR ABSTRACT:"LIGHTR" OR TITLE:"CD270" OR ABSTRACT:"CD270") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNFRSF14, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPOU2AF1
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetBCL6
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCIITA
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetEBF1
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetP2RY8
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetPAX5
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetTBL1XR1
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetBCL10
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.